Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher
PTC Therapeutics, Inc. (PTCT - Free Report) was a big mover last session, as the company saw its shares rise nearly 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $16.8–$21.6 in the past one-month time frame, witnessed a sharp increase on Friday.
The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
PTC Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
PTC Therapeutics, Inc. Price and Consensus
PTC Therapeutics, Inc. Price and Consensus | PTC Therapeutics, Inc. Quote
A better ranked stock in the Medical - Drugs industry is MEI Pharma, Inc..(MEIP - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PTCT going up? Or down? Predict to see what others think: Up or Down
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>